Erasca (NASDAQ: ERAS)
$1.48
(-2.9%)
-$0.04
Price as of June 13, 2025, 3:17 p.m. ET
Erasca Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Erasca Company Info
Erasca, Inc. is a clinical stage precision oncology company, It focuses on discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim on July 2, 2018 and is headquartered in San Diego, CA.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.